Thyrocare Technologies Limited, a leading healthcare diagnostics company, has announced the launch of its state-of-the-art genomics laboratory in Navi Mumbai.

With this, Thyrocare expands its portfolio with a new range of speciality tests in genomics, powered by a state-of-the-art facility equipped with advanced next-generation sequencing technologies and supported by robust bioinformatics and data interpretation capabilities.

Thyrocare Technologies has already achieved 100 per cent NABL accreditation across all its laboratories.

Thyrocare said that the new lab is designed for high-throughput genomic analysis. The laboratory enables accurate, consistent, and scalable testing, delivering high standards of reporting excellence.

Rahul Guha, MD & CEO, Thyrocare and API Holdings, said that the launch of genomics laboratory marks a significant step as the company expands into advanced, high-impact areas of testing.

"With this expansion, we aim to make advanced genomics testing more accessible and affordable while continuing to build on our proven model of high-throughput, quality-driven diagnostics,” Rahul said.

"The launch of the new genomics lab by Thyrocare in Mumbai highlights a pivotal shift towards preventive and data-driven healthcare in India. By the integration of advanced genetic insights with its strong diagnostic network, the company aims to support a more data-driven, preventive and personalised approach to healthcare in India," Ramesh Kinha, COO, Thyrocare, said. 

Thyrocare Technologies launches Bharat Aarogyam Score - details